Webinar-Recorded

Webinar- Overcoming Scalability Challenges with Autologous Therapies

"Autologous immunotherapies have evolved in recent years to bring breakthrough treatments to the market. However, the complexity of the production process often results in extended timelines and high manufacturing costs, limiting the scalability and application across therapeutic indications. Therefore, cell therapy providers continue to make new investments to develop standardized and optimized scale-out strategies while balancing the customized processes for each patient treatment. In this webinar, Catalent presents a clinical-to-commercial perspective on autologous therapies. Professor Gerhard Bauer discusses the current challenges associated with autologous therapies and Dr. James Crutchley speaks to the various solutions available for commercial scale-up of advanced therapeutics."

Learn more about:

Challenges, advantages and disadvantages of several systems that are currently available for manufacturing of these advanced therapies

Manufacturing by Design Methodology developed by Catalent to deliver process efficiencies and scalability

How to achieve economies of scale by optimizing across the manufacturing supply chain

Business Email Address*

First Name*

Last Name*

Company*

Title*

Business Phone

Country

State or Province

Buying Horizon*

Asset ID

Asset Type

Asset URL

Download Center - Date Stamp

Download Center - Visit Count

ZZ - Last SFDC Campaign ID

Unique ID

Browser

auxCountry

auxState

Why Catalent?

Catalyst + Talent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™